Sign in

    Manos Mastorakis

    Research Analyst at Deutsche Bank

    Manos Mastorakis is a Research Analyst at Deutsche Bank AG, specializing in the biotechnology and pharmaceutical sectors, with a focus on European biopharma companies such as Galapagos NV. He regularly covers earnings calls and provides in-depth analysis of strategic developments, M&A, and regulatory milestones for leading biotech firms, consistently cited for his insights in quarterly reports throughout 2023 and 2024. Mastorakis began his career in equity research and has developed expertise in pipeline evaluation and financial modeling, contributing to Deutsche Bank's research division in recent years. He holds recognized industry accreditations supporting his role as a lead research analyst, reflecting a strong background in financial analysis and biopharma market trends.

    Manos Mastorakis's questions to GALAPAGOS (GLPG) leadership

    Manos Mastorakis's questions to GALAPAGOS (GLPG) leadership • Q1 2025

    Question

    Manos Mastorakis requested more color on SpinCo's M&A strategy, its degree of independence from Galapagos, and the expected timeline for executing its first deals.

    Answer

    CFO Thad Huston clarified that SpinCo will be a fully independent company, with new CEO Henry Gosebruch and its board responsible for setting the M&A strategy. CEO Paulus Stoffels added that while deal preparation is active, transactions are not expected to be executed until after the separation is completed mid-year.

    Ask Fintool Equity Research AI

    Manos Mastorakis's questions to ARGENX (ARGX) leadership

    Manos Mastorakis's questions to ARGENX (ARGX) leadership • Q4 2024

    Question

    Manos Mastorakis asked about the potential for competitors to improve upon efgartigimod's clinical outcomes in CIDP and whether complement inhibitors have a role to play in the disease.

    Answer

    CEO Tim Van Hauwermeiren asserted that argenx has set a very high bar with a 70% response rate in CIDP. He confirmed his belief that complement does have a role, which is why the company is advancing its C2 inhibitor, empasiprubart, in CIDP. This could potentially serve the 30% of non-responders, including patients with pathogenic IgM autoantibodies.

    Ask Fintool Equity Research AI

    Manos Mastorakis's questions to ARGENX (ARGX) leadership • Q1 2024

    Question

    Manos Mastorakis asked about the key learnings from the portfolio review that led to the ANCA vasculitis discontinuation and how those learnings were applied to the empasiprubart programs.

    Answer

    CEO Tim Van Hauwermeiren explained the portfolio review was comprehensive, covering both efgartigimod and empasiprubart. The team thoroughly assessed the impact of background medications on trial designs. This exercise reinforced confidence in all empasiprubart programs, concluding that medication interference was manageable, unlike in AAV where the risk was deemed too high.

    Ask Fintool Equity Research AI

    Manos Mastorakis's questions to BioNTech (BNTX) leadership

    Manos Mastorakis's questions to BioNTech (BNTX) leadership • Q3 2024

    Question

    Manos Mastorakis asked about the company's ongoing confidence in its TROP-2 ADC program (BNT325) and its iNeST personalized cancer vaccine program.

    Answer

    Chief Medical Officer Dr. Özlem Türeci and Chief Strategy Officer Ryan Richardson responded. Dr. Türeci highlighted the potential for the TROP-2 ADC in combination with BNT327 and noted the iNeST platform is expanding with three ongoing randomized trials in adjuvant settings. Mr. Richardson added that the company continues to believe iNeST has disruptive potential, particularly in adjuvant settings, and is investing accordingly.

    Ask Fintool Equity Research AI